Comparative Pharmacology
Head-to-head clinical analysis: BOSUTINIB MONOHYDRATE versus OFEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSUTINIB MONOHYDRATE versus OFEV.
BOSUTINIB MONOHYDRATE vs OFEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a dual Src/Abl tyrosine kinase inhibitor. It inhibits the BCR-ABL kinase, which is constitutively active in chronic myeloid leukemia (CML), and also inhibits Src family kinases. It has minimal inhibitory activity against c-KIT and PDGFR.
Nintedanib is a tyrosine kinase inhibitor that blocks the activity of fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR), thereby inhibiting fibroblast proliferation, migration, and transformation, and reducing extracellular matrix deposition.
400 mg orally once daily with food.
150 mg orally twice daily, taken with food.
None Documented
None Documented
22.5 hours; supports once-daily dosing, with steady-state achieved by day 8.
Terminal elimination half-life is approximately 38 hours (range 30–48 hours) at steady state, supporting once-daily dosing.
Primarily fecal (91%, as unchanged drug and metabolites) with renal excretion accounting for <3%.
Primarily biliary/fecal (~93.4% of total radioactivity recovered in feces), renal excretion is minor (~0.6% unchanged in urine).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor